• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Zyoptix XP microkeratome reported to produce predictable, more accurate LASIK flaps

Article

Data presented at the American Academy of Ophthalmology annual meeting from the first head-to-head contralateral study comparing the outcomes of the latest Bausch & Lomb microkeratome technology against the Intralase Femtosecond (FS) device show that the new Bausch & Lomb Zyoptix XP microkeratome:

Chicago-Data presented at the American Academy of Ophthalmology annual meeting from the first head-to-head contralateral study comparing the outcomes of the latest Bausch & Lomb microkeratome technology against the Intralase Femtosecond (FS) device show that the new Bausch & Lomb Zyoptix XP microkeratome:

• Was statistically significantly more accurate with respect to intended flap thickness.

• Produced on average thinner corneal flaps with respect to intended flap thickness.

• Had a comparable standard deviation in flap thickness.

• Demonstrated equivalent uncorrected and best-corrected visual acuity under high- and low-light contrast conditions.

“The study findings strongly suggest that surgeons who use the Zyoptix XP microkeratome can expect to achieve the same level of precision, predictability, and outcomes that have been ascribed to the latest generation laser flap-creation technology,” said lead investigator Hung Ming Lee, MD.

The prospective, randomized, controlled, contralateral eye study compared flap thickness as measured by both conventional ultrasound pachymetry and advanced optical coherence pachymetry. The study results were based on 98 eyes of 49 patients.

More information is available at the Bausch & Lomb Booths 2907 and 3204.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.